Top Suppliers:I want be here


1846570-31-7

1846570-31-7 structure
1846570-31-7 structure
  • Name: CM-272
  • Chemical Name: 6-Methoxy-2-(5-methyl-2-furyl)-N-(1-methyl-4-piperidinyl)-7-[3-(1-pyrrolidinyl)propoxy]-4-quinolinamine
  • CAS Number: 1846570-31-7
  • Molecular Formula: C28H38N4O3
  • Molecular Weight: 478.626
  • Catalog: Signaling Pathways Apoptosis Apoptosis
  • Create Date: 2020-01-11 18:13:51
  • Modify Date: 2024-01-11 11:15:23
  • CM-272 (CM272) is a novel potent, selective and reversible dual inhibitor of G9a/DNMTs with IC50 of 8 nM and 382 nM for G9a and DNMT1, respectively; also inhibits DNMT3A/3B/GLP with IC50 of 85/1,200/2 nM, respectively; inhibits cell proliferation and promotes apoptosis in different haematological neoplasias (AML, ALL and DLBCL); significantly prolongs survival of AML, ALL and DLBCL xenogeneic models.

Name 6-Methoxy-2-(5-methyl-2-furyl)-N-(1-methyl-4-piperidinyl)-7-[3-(1-pyrrolidinyl)propoxy]-4-quinolinamine
Synonyms 6-Methoxy-2-(5-methyl-2-furyl)-N-(1-methyl-4-piperidinyl)-7-[3-(1-pyrrolidinyl)propoxy]-4-quinolinamine
4-Quinolinamine, 6-methoxy-2-(5-methyl-2-furanyl)-N-(1-methyl-4-piperidinyl)-7-[3-(1-pyrrolidinyl)propoxy]-
Description CM-272 (CM272) is a novel potent, selective and reversible dual inhibitor of G9a/DNMTs with IC50 of 8 nM and 382 nM for G9a and DNMT1, respectively; also inhibits DNMT3A/3B/GLP with IC50 of 85/1,200/2 nM, respectively; inhibits cell proliferation and promotes apoptosis in different haematological neoplasias (AML, ALL and DLBCL); significantly prolongs survival of AML, ALL and DLBCL xenogeneic models.
Related Catalog
Target

G9a:8 nM (IC50)

GLP:2 nM (IC50)

DNMT1:382 nM (IC50)

DNMT3A:85 nM (IC50)

DNMT3B:1200 nM (IC50)

In Vitro CM-272 (100-1000 nM; 12-72 hours; CEMO-1, MV4-11 and OCI-Ly10 cell lines) treatment inhibits cell proliferation in a dose- and time-dependent manner[1]. CM-272 (100-1000 nM; 24 hours; CEMO-1, MV4-11 and OCI-Ly10 cell lines) treatment blocks cell cycle progression[1]. CM-272 (100-1000 nM; 12-72 hours; CEMO-1, MV4-11 and OCI-Ly10 cell lines) treatment induces apoptosis in ALL, AML and DLBCL cell lines in a dose- and time-dependent manner[1]. CM-272 after 48 h of treatment CEMO-1 acute lymphoblastic leukaemia (ALL) cell line, MV4-11 acute myeloid leukaemia (AML) cell line and OCI-Ly10 diffuse large B-cell lymphoma (DLBCL) cell line, the GI50 values of 218 nM, 269 nM and 455 nM, respectively, and is associated with a decrease in global levels of H3K9me2 and 5mC[1]. The therapeutic activity of CM-272 relies on the early activation of the type I IFN response in tumour cells, potentially leading to the induction of cell autonomous immunogenic death in tumour cells[1]. Cell Proliferation Assay[1] Cell Line: CEMO-1, MV4-11 and OCI-Ly10 cell lines Concentration: 125 nM, 250 nM, 500 nM (CEMO-1 cells); 135 nM, 270 nM, 540 nM (MV4-11 cells); 100 nM, 400 nM, 1000 nM (OCI-Ly10 cells) Incubation Time: 12 hours, 24 hours, 48 hours and 72 hours Result: Inhibited cell proliferation in a dose- and time-dependent manner. Cell Cycle Analysis[1] Cell Line: CEMO-1, MV4-11 and OCI-Ly10 cell lines Concentration: 125 nM, 250 nM, 500 nM (CEMO-1 cells); 135 nM, 270 nM, 540 nM (MV4-11 cells); 100 nM, 400 nM, 1000 nM (OCI-Ly10 cells) Incubation Time: 24 hours Result: Blocked cell cycle progression. Apoptosis Analysis[1] Cell Line: CEMO-1, MV4-11 and OCI-Ly10 cell lines Concentration: 125 nM, 250 nM, 500 nM (CEMO-1 cells); 135 nM, 270 nM, 540 nM (MV4-11 cells); 100 nM, 400 nM, 1000 nM (OCI-Ly10 cells) Incubation Time: 12 hours, 24 hours, 48 hours and 72 hours Result: Induced apoptosis in ALL, AML and DLBCL cell lines in a dose- and time-dependent manner.
In Vivo CM-272 (2.5 mg/kg; intravenous injection; daily; for 28 days; female Rag2−/−γc−/− mice) treatment significantly prolongs survival of CEMO-1 cells xenogeneic models[1]. Animal Model: Female BALB/Ca-Rag2−/−γc−/− mice (6–8-week-old) with CEMO-1 cells[1] Dosage: 2.5 mg/kg Administration: Intravenous injection; daily; for 28 days Result: Induced a statistically significant increase in overall survival (OS) in mice.
References

[1]. San José-Enériz E, et al. Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies. Nat Commun. 2017 May 26;8:15424.

Density 1.2±0.1 g/cm3
Boiling Point 631.9±55.0 °C at 760 mmHg
Molecular Formula C28H38N4O3
Molecular Weight 478.626
Flash Point 336.0±31.5 °C
Exact Mass 478.294403
LogP 5.41
Vapour Pressure 0.0±1.9 mmHg at 25°C
Index of Refraction 1.601
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.